EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sodium proton antiport activity and cell growth in cultured skin fibroblasts of iddm patients with nephropathy



Sodium proton antiport activity and cell growth in cultured skin fibroblasts of iddm patients with nephropathy



Diabetes 41(10): 1239-1246



IDDM patients with incipient and overt nephropathy have been found to exhibit an overactivity of RBC sodium-lithium countertransport. To explore the physiological relevance of this finding, we measured the activity of Na+/H+ antiport in serially passaged cultured skin fibroblasts from IDDM patients with and without nephropathy and from normal, nondiabetic control subjects. Na+/H+ antiport activity (measured as the rate of amiloride-sensitive Na+ influx at pHi = 6.4, extracellular pH = 8.0, and [Na+] = 1 mM) was elevated significantly in IDDM patients with nephropathy compared with IDDM patients without nephropathy and nondiabetic control subjects (13.35 .+-. 3.8 vs. 8.54 .+-. 2.0 vs. 7.33 .+-. 2.3 nmol Na+ .cntdot. mg protein-1 .cntdot. min-1; P < 0.006 and P < 0.001, respectively). A kinetic analysis of Na+/H+ antiport activity showed that the raised activity in IDDM patients with nephropathy was caused by an increased Vmax for extracellular Na+. Km values were similar in the three groups. pH-stimulated amiloride-sensitive Na+ influx also was higher under baseline conditions and after serum stimulation in cells from IDDM patients with nephropathy. pHi values were significantly higher, both during active proliferation and after 10-min exposure to serum, in cells from IDDM patients with nephropathy, compared with IDDM patients without nephropathy and nondiabetic control subjects. Serum-stimulated incorporation of [3H]thymidine into DNA was greater in IDDM patients with nephropathy than in the other two groups (35.7 .+-. 18.9- vs. 17.4 .+-. 7.5- vs. 11.9 .+-. 8.7-fold stimulation above baseline; P < 0.01 for both). These data from cultured skin fibroblasts suggest that intrinsic abnormalities in cell function, independent of the metabolic disturbances of diabetes, are characteristic of IDDM patients who develop nephropathy.

(PDF emailed within 1 workday: $29.90)

Accession: 007801072

Download citation: RISBibTeXText



Related references

Na+/H+ antiport activity and cell growth in cultured skin fibroblasts of IDDM patients with nephropathy. Diabetes 41(10): 1239-1246, 1992

Enhanced growth and sodium-proton antiport activity response to serum in cultured fibroblasts of diabetic patients with nephropathy. Acta Diabetologica 29(3-4): 178-181, 1992

Overactivity of sodium proton antiport and enhanced cell growth in fibroblasts of type 1 insulin dependent diabetic patients with nephropathy. Diabetologia 32(7): 549A, 1989

Intracellular pH and sodium, proton antiport activity of cultured skin fibroblasts from diabetics. Kidney International 42(5): 1184-1190, 1992

Proliferation and sodium-proton antiport activity in human fibroblasts from type I diabetic patients with nephropathy. American Journal of Hypertension 6(2): 170-173, 1993

Overactivity of sodium proton antiport and enhanced cell growth in fibroblasts of type 1 insulin dependent diabetics with nephropathy. Kidney International 37(1): 199, 1990

Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na+/H+ antiporter. Kidney International 50(5): 1684-1693, 1996

Enhanced proliferation in cultured skin fibroblasts from patients with type I diabetes and nephropathy Role of sodium-proton antiporter. Journal Of The American Society Of Nephrology. 3(3): 761, 1992

Sodium proton antiport activity in skin fibroblasts from blacks and whites. Hypertension (Dallas) 15(2): 140-145, 1990

Leukocyte sodium proton antiport activity in type 1 insulin dependent diabetic patients with nephropathy. Diabetologia 33(6): 371-377, 1990

Platelet sodium proton antiport activity in patients with insulin dependent diabetes mellitus with and without diabetic nephropathy. Journal of the American Society of Nephrology 2(3): 288, 1991

Decreased activity of calcium pump in skin fibroblasts of IDDM patients with nephropathy. Diabetologia 40(SUPPL 1): A541, 1997

Cytotoxic t lymphocyte ctl mediated cytolysis proceeds in the absence of sodium proton antiport activity regulation of cytosolic ph by the sodium proton antiport in a cloned ctl. Cellular Immunology 135(1): 208-221, 1991

Blockade of the sodium proton antiport abolishes growth factor induced dna synthesis in fibroblasts structure activity relationships in the amiloride series. Journal of Biological Chemistry 259(7): 4313-4319, 1984

Acid activation of sodium-proton antiport activity in a cultured mouse medullary collecting duct cell line. Journal of the American Society of Nephrology 3(3): 779, 1992